The Weight of Care: How Healthcare Became One of the Planet’s Largest Emitters

There is an inherent tension at the centre of modern healthcare: the institutions and companies devoted to extending life are simultaneously accelerating the environmental conditions that threaten it. The pharmaceutical sector alone generates carbon emissions equivalent to more than 514 coal power plants annually, and the broader healthcare system — including hospitals, supply chains, medical devices, and clinical research — accounts for approximately 4.4% of global CO₂ emissions, according to a comprehensive review published in 2026 examining sustainability management in healthcare organisations. That figure exceeds the aviation industry’s share and has continued to rise annually as the sector expands.

Understanding why requires looking at the structure of healthcare’s carbon footprint. Scope 1 emissions — those generated directly by a company’s own operations — and Scope 2 emissions from purchased electricity are significant, but they are the portion of the problem that companies have most successfully addressed. The harder, and more consequential, challenge is Scope 3, which encompasses the full value chain: raw material sourcing, contract manufacturing, clinical trial logistics, packaging, distribution, and the end-use of products. For pharmaceutical companies, Scope 3 is estimated to represent as much as 80% of total emissions — a figure that makes operational improvements at headquarters or manufacturing sites necessary but insufficient.

What Mandatory Reporting Is Changing

The ESG regulatory environment of 2026 looks meaningfully different from even two years ago, and the trajectory is toward more disclosure rather than less, despite countervailing political forces. The European Union’s Corporate Sustainability Reporting Directive (CSRD) remains the most far-reaching mandatory reporting framework globally. While a recent EU Omnibus package is expected to reduce the number of companies directly in scope — lawyers at Ropes & Gray estimate the changes will remove around 90% of companies from CSRD coverage — the framework still covers the world’s largest multinationals, which includes virtually every major pharmaceutical and biotech company that operates globally.

The shift from voluntary, narrative-heavy sustainability reports to mandatory, data-driven disclosures subject to third-party assurance is, in the assessment of practitioners at Donnelley Financial Solutions, the defining ESG development of the current cycle. Companies are now building SOX-style internal controls around emissions data, with traceability, documentation, and management sign-off requirements that did not exist three years ago. For healthcare companies, this means that the emissions numbers they publish are subject to scrutiny previously reserved for financial statements. The consequences of inaccuracy — reputational, legal, and increasingly financial — have risen accordingly.

In the United States, the political environment has moved in the opposite direction. The Trump administration’s Executive Order 14366, signed in late 2025 and moving into enforcement in 2026, directed the SEC to strip ESG mandates from the proxy voting ecosystem and narrow the definition of materiality in shareholder proposals. The Department of Labor simultaneously reversed Biden-era ERISA rules that had allowed pension fund managers to consider non-pecuniary factors. Healthcare companies with dual US and EU exposure must now navigate genuinely divergent regulatory regimes — complying with European mandatory disclosure while managing the political risk of prominent ESG communication in American markets.

The Industry’s Carbon Leadership — and Its Gaps

Despite the structural challenge, a core group of pharmaceutical companies has made credible and measurable progress. All 18 major pharmaceutical companies analysed by GlobalData have committed to emissions reduction or net-zero targets. AstraZeneca, which announced its Ambition Zero Carbon strategy in 2020 targeting carbon neutrality across the entire value chain by 2030, reduced its Scope 1 and 2 emissions by 59% between 2015 and 2021 and has set the industry’s most ambitious supplier target, requiring 95% of its suppliers to hold science-based emissions reduction targets by 2025. Amgen reduced operational emissions by 44% between 2019 and 2022, leading the sector’s top performers.

Sanofi appeared in the tenth slot of Time’s World’s Most Sustainable Companies 2025 ranking, with Novartis eleventh and AstraZeneca nineteenth. The presence of pharmaceutical companies — alongside energy companies and heavy industrials — in that ranking reflects genuine sector momentum, but it also illustrates how much distance remains between current performance and the net-zero timelines these companies have publicly committed to.

The defining sustainability challenge of the decade, as the 2025 Carbon Impact of Biotech & Pharma Report concluded, is Scope 3. Collective action through shared frameworks, consistent supplier expectations, and transparent data produces measurably better results than unilateral programmes, the report found — but the industry must accelerate its pace significantly to align with 1.5°C pathways. Of the 600-plus companies included in the analysis, only 31% had targets aligned with that threshold. The other 69% have the commitments, the communications, and in many cases the intentions. What they lack is the speed.

Why This Matters Beyond Reputation

The commercial stakes of ESG performance in healthcare are no longer purely reputational. MSCI ESG Ratings, used by pension funds, sovereign wealth funds, and asset managers globally, assess companies’ resilience to financially material sustainability risks on a scale from CCC to AAA. A significant historical correlation exists between MSCI ESG ratings and financing costs in equity and debt markets. For healthcare companies seeking to access institutional capital at competitive terms — which is to say, virtually all of them — ESG performance is increasingly a factor in the cost of capital, not merely in press releases.

The 2024 Ernst & Young study of 300 pharmaceutical companies found that companies implementing comprehensive ESG programmes showed 31% lower operating costs after three years — a finding that reframes the sustainability conversation from expense to investment. Companies that treat ESG as a leadership opportunity rather than a compliance exercise create, on average, significantly more enterprise value than those that treat it as a reporting burden. Novartis’s carbon-neutral manufacturing, the study found, produced 28% cost savings alongside improved community health metrics. GSK’s transparent clinical trials system increased patient trust scores by 45%. Those are not soft outcomes.

Author

Bernice Lottering